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Recycling Between Cortisol and Cortisone in Human
Splanchnic, Subcutaneous Adipose, and Skeletal
Muscle Tissues In Vivo
Katherine A. Hughes,1 Konstantinos N. Manolopoulos,2 Javaid Iqbal,1 Nicholas L. Cruden,1
Roland H. Stimson,1 Rebecca M. Reynolds,1 David E. Newby,1 Ruth Andrew,1 Fredrik Karpe,2 and
Brian R. Walker1
11b-Hydroxysteroid dehydrogenase type 1 (11bHSD1) is a thera-
peutic target in metabolic syndrome because it catalyses reduc-
tase regeneration of cortisol from cortisone in adipose and
liver. 11bHSD1 can also catalyze the reverse dehydrogenase
reaction in vitro (e.g., if cofactor is limited). We used stable
isotope tracers to test the hypothesis that both 11bHSD1-
reductase and -dehydrogenase activities occur in human metabolic
tissues in vivo. 1,2-[2H]2-Cortisone (d2-cortisone) was validated as
a tracer for 11b-dehydrogenase activity and its inhibition by lico-
rice. d2-Cortisone and 9,11,12,12-[2H]4-cortisol (d4-cortisol) (to mea-
sure 11b-reductase activity) were coinfused and venous samples
obtained from skeletal muscle, subcutaneous adipose (n = 6), and
liver (n = 4). Steroids were measured by liquid chromatography–
tandem mass spectrometry and arteriovenous differences ad-
justed for blood ﬂow. Data are means 6 SEM. 11b-Reductase
and -dehydrogenase activities were detected in muscle (cortisol
release 19.7 6 4.1 pmol/100 mL/min, d3-cortisol 5.9 6 1.8 pmol/
100 mL/min, and cortisone 15.2 6 5.8 pmol/100 mL/min) and
splanchnic (cortisol 64.0 6 11.4 nmol/min, d3-cortisol 12.9 6
2.1 nmol/min, and cortisone 19.5 6 2.8 nmol/min) circulations.
In adipose, dehydrogenase was more readily detected than re-
ductase (cortisone release 38.7 6 5.8 pmol/100 g/min). Active
recycling between cortisol and cortisone in metabolic tissues in
vivo may facilitate dynamic control of intracellular cortisol but
makes consequences of dysregulation of 11bHSD1 transcription
in obesity and diabetes unpredictable. Disappointing efﬁcacy of
11bHSD1 inhibitors in phase II studies could be explained by
lack of selectivity for 11b-reductase.Diabetes 61:1357–1364, 2012
G
lucocorticoids are key regulators of fuel me-
tabolism. In recent years, it has become clear
that in addition to tight control of circulating
cortisol by the hypothalamic-pituitary-adrenal
axis, intracellular cortisol levels are controlled by local
metabolism (1). For example, recent studies using a stable
isotope tracer, 9,11,12,12-[2H]4-cortisol (d4-cortisol) (2),
have demonstrated that in vivo hepatic and subcutane-
ous adipose 11b-hydroxysteroid dehydrogenase type 1
(11bHSD1) regenerates cortisol from inert cortisone, re-
leasing ;900 and 15 pmol of cortisol/100 g tissue/min, re-
spectively (3,4). This 11bHSD1-reductase activity is driven
by NADPH cofactor derived from hexose-6-phosphate de-
hydrogenase (H6PDH), colocalized with 11bHSD1 in the
endoplasmic reticulum lumen (5). Altered cortisol gener-
ation in tissues such as adipose and liver has been impli-
cated in the metabolic complications of obesity (6,7), and
11bHSD1 inhibition is a potential therapeutic target to
lower intracellular cortisol levels in type 2 diabetes (8,9).
However, phase 2 trials with small-molecule inhibitors
have delivered mixed results (10,11).
One factor that may contribute to unpredictable efﬁcacy
of 11bHSD1 inhibitors is the potential reversibility of reac-
tions catalyzed by 11bHSD1. In states of NADPH deﬁciency,
11bHSD1 can switch direction and exhibit predominant
dehydrogenase activity, e.g., when 11bHSD1 is liberated
from the intracellular environment or when H6PDH is
disrupted by gene targeting in mice (12). Adipose 11b-
dehydrogenase activity, inactivating cortisol to cortisone,
has been demonstrated in primary cell cultures and dur-
ing intra-adipose microdialysis in vivo (13,14). As adipose
11bHSD2 expression is negligible and 11bHSD1 expres-
sion is abundant (15), this dehydrogenase activity may be
attributed to 11bHSD1 and be metabolically protective
(16). However, whether it is of sufﬁcient magnitude to
inﬂuence intracellular cortisol concentrations has not
been determined.
11bHSD1 is also expressed in liver (3) and skeletal
muscle (17)—both important sites of insulin resistance in
type 2 diabetes. d4-Cortisol infusion conﬁrms the liver as
a major source of extra-adrenal cortisol production by
11b-reductase (3,4,18). A decline in cortisone concentra-
tion between arterial and portal vein samples (4) suggests
that there is also 11b-dehydrogenase in the splanchnic
circulation. This is most likely attributable to 11bHSD2 in
the gut; whether there is 11b-dehydrogenase activity in the
liver is unknown. In rodents, skeletal muscle 11bHSD1
activity is low compared with adipose and liver (19), while
in humans evidence for in vivo skeletal muscle 11bHSD1
activity is equivocal, as no gradients in cortisol or corti-
sone concentrations were found across forearm muscle
(20) but a small amount of reductase activity was detected
in the leg using d4-cortisol (18,21). Ex vivo studies have
demonstrated skeletal muscle 11bHSD1-reductase activity
and a small amount of 11bHSD1-dehydrogenase activity in
tissue homogenates (22). Since 11bHSD1 expression in
skeletal muscle is higher in diabetes (23), it is important to
clarify its function.
d4-Cortisol allows quantiﬁcation of 11b-reductase be-
cause the deuterium in the 11a position is removed by 11b-
dehydrogenase to form d3-cortisone, which in turn is
regenerated to d3-cortisol by incorporation of a proton;
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dilution of d4-cortisol by d3-cortisol exclusively reﬂects
11b-reductase activity (2). It is not possible to quantify 11b-
dehydrogenase during steady-state infusion of d4-cortisol
because the rate of appearance (Ra) of d3-cortisone cannot
be quantiﬁed without infusing a tracer into the cortisone
pool. For this purpose, we have developed a novel tracer
method with 1,2-[2H]2-cortisone (d2-cortisone) and used it in
combination with d4-cortisol to measure simultaneous
11b-dehydrogenase and reductase activities in vivo. We used
these isotopes in conjunction with arteriovenous sampling
to test the hypothesis that there is interconversion of cor-
tisol and cortisone in subcutaneous adipose, splanchnic,
and skeletal muscle tissues.
RESEARCH DESIGN AND METHODS
Chemicals and reagents. Reagents were obtained from Sigma (Poole, U.K.),
Steraloids (Newport, RI), or VWR (Lutterworth, U.K.) unless otherwise spec-
iﬁed. Solvents were high-performance liquid chromatography grade from
Fisher Scientiﬁc (Loughborough, U.K.). d2-Cortisone, 1,2-[2H]2-cortisol (d2-
cortisol), and d4-cortisol were obtained from Cambridge Isotope Laborato-
ries (Andover, MA), and unlabeled cortisol was obtained from Calbiochem
(Nottingham, U.K.), indocyanine green (ICG) from Pulsion Medical (Middlesex,
U.K.), and 1,2-[3H]2-cortisone from GE Healthcare UK (Little Chalfont, U.K.).
In vitro validation of d2-cortisone tracer. To establish that d2-cortisone is a
substrate for human 11bHSD1, human embryonic kidney (HEK)293 cells (2 3
105) stably transfected with human 11bHSD1 (24) were incubated (1–24 h, n = 6)
with d2-cortisone or cortisone (2 mmol/L). Steroids were extracted and ana-
lyzed by liquid chromatography–tandem mass spectrometry.
For assessment of any primary isotope effect, HEK293/h11bHSD1 cells
(2 3 105) were incubated (6–24 h, n = 6) with [3H]2-cortisone (5 nmol/L) and
cortisone or d2-cortisone (0–4,955 nmol/L). Media was extracted and [3H]2-steroids
quantiﬁed by HPLC with online b-scintillation counting (Berthold LB509 de-
tector; Berthold Technologies, Harpenden, U.K.).
To compare metabolism by other enzymes, human liver cytosol (25.21
mg/mL protein) was incubated (n = 6, 37°C, 8 h) with [3H]2-cortisone (10 nmol/L)
and either cortisone or d2-cortisone (10 mmol/L), in the presence of a cofactor-
generating system (2 mmol/L NADPH), glucose-6-phosphate (5 mmol/L), and
glucose-6-phosphate dehydrogenase (0.5 units/250 mL). The reaction was ter-
minated with ethyl acetate (10 vol), and the solvent extracts were analyzed by
HPLC, with products identiﬁed by comparison of retention times with un-
labeled standards detected by absorbance at l 244 nm for cortisone and 195
nm for reduced metabolites.
Clinical protocols. All studies were approved by the local research ethics
committee, and written informed consent was obtained. Participants had normal
blood indices (hemoglobin, renal function, and glucose) and had not received
glucocorticoid treatment by any route for 3 months prior to the studies.
In vivo pharmacokinetics of d2-cortisone. For calculation of pharmaco-
kinetics and estimation of a steady-state infusion rate, three healthy lean men
received an intravenous bolus of d2-cortisone (141 mg in 0.9% saline, wt/vol
50 mL) over 5 min with venous blood sampled at intervals for 90 min from the
contralateral arm.
For measurement of endogenous cortisone production rate at steady state
and for testing the effect of inhibition of 11b-dehydrogenase with licorice, three
healthy lean men attended on two occasions, once before and a second time
after eating 200 g black licorice (Panda licorice chews, 3.8% licorice extract;
Panda, Vaajakoski, Finland) daily for 2 days. A priming dose (76 mg in 0.9%
saline, wt/vol) and a 3-h infusion of d2-cortisone (105.3 mg/h, 0.9% saline,
wt/vol) were administered. Venous blood was sampled at intervals (Fig. 1).
Cortisol/cortisone interconversion in subcutaneous adipose and
skeletal muscle. Six healthy lean men attended after an overnight fast in
a quiet temperature-controlled (24°C) room. A cannula (18G) was placed
anterogradely into a right antecubital fossa vein for infusions. Retrograde 20G
cannulae were placed as follows: 1) in a superﬁcial vein on the anterior ab-
dominal wall, under ultrasonic guidance, to sample from subcutaneous adipose
(25); 2) in a deep branch of the median cubital vein in the left antecubital fossa
FIG. 1. In vivo d2-cortisone administration. A: Plasma d2-cortisone concentrations after an intravenous bolus of d2-cortisone without licorice.
B: Plasma cortisone concentrations after infusion of tracer with and without prior licorice administration. C: Plasma enrichment of cortisone with
d2-cortisone following infusion of tracer with and without prior licorice administration. D: Plasma d2-cortisone concentrations following infusion
of tracer with and without prior licorice administration. All data are means 6 SEM for n = 3. For statistical comparisons, see Table 1.
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to sample from forearm skeletal muscle (26); and 3) in a dorsal vein of the right
hand, with the hand warmed to 60°C to sample arterialized blood (27). For
conﬁrmation of correct placement of cannulae, O2 saturation (GEM OPL; In-
strumentation Laboratory, Bedford, MA) was conﬁrmed to be .85, ,40, and
.98% in the adipose, skeletal muscle, and arterialized samples, respectively.
d2-Cortisone and d4-cortisol (40% in cortisol) were administered in 0.9%
saline, wt/vol, as intravenous boluses of 76.0 mg and 3.5 mg followed by
continuous intravenous infusions of 105.3 mg/h and 1.74 mg/h, respectively.
Arterialized samples were obtained preinfusion and at hourly intervals for 3 h.
From 3 h, four sets of blood samples were obtained simultaneously from all
sites at 10-min intervals. Prior to taking of samples from the deep forearm
vein, a wrist cuff was inﬂated to 200 mmHg for 2 min to remove blood ﬂow
from the hand. Forearm blood ﬂow was measured by venous occlusion
plethysmography (28) (Hokanson, Bellevue, WA) immediately after sampling
using the mean of three readings during intermittent occlusion of the upper
arm with a cuff inﬂated to 40 mmHg. Adipose tissue blood ﬂow was measured
continuously during the study using a Mediscint g-counter probe after a sub-
cutaneous injection of 1–2 MBq 133Xe lateral to the umbilicus (29).
Cortisol/cortisone interconversion in the splanchnic circulation. For
facilitation of ethical hepatic vein cannulation, four patients undergoing
elective coronary angiography for investigation of coronary artery disease
were studied. Two venous cannulae (20G) were sited in peripheral veins. d2-
Cortisone and d4-cortisol (20% in cortisol) were administered in 0.9% saline, wt/
vol, as intravenous boluses of 75.6 mg and 3.5 mg followed by continuous
intravenous infusions of 104.8 mg/h and 1.74 mg/h, respectively. A simulta-
neous infusion of intravenous ICG (30 mg/h constituted in water for injection)
was used to estimate liver blood ﬂow. After infusion for at least 3 h, femoral
arterial and venous sheaths were inserted and participants underwent coro-
nary angiography with follow-on percutaneous coronary intervention when
indicated. Upon completion of the clinical procedure, cannulation of the he-
patic vein was undertaken under ﬂuoroscopic guidance via the venous sheath
using a Swan-Ganz double lumen catheter (6F; Edward Life Sciences, Irvine,
CA). A series of three paired blood samples was drawn simultaneously from
hepatic vein and femoral artery.
Laboratory analysis. Blood samples were collected in lithium heparin and
plasma stored at 280°C until analysis. Cortisol, d4-cortisol, d3-cortisol, d2-
cortisol, cortisone, and d2-cortisone were extracted from plasma (1.5–2.0 mL)
enriched with epicortisol (500 ng) using chloroform (15–20 mL) and analyzed
using liquid chromatography–tandem mass spectrometry as previously de-
scribed (4), except that chromatographic separation was optimized using
a Restek Biphenyl Allure column (5 mm, 10 cm, 4.6 mm, 38°C, and 0.5 mL/min).
The most abundant ions for analysis of the deuterated and nondeuterated
steroids were selected by tuning on a TSQ Quantum Discovery Mass spec-
trometer, and conditions for multiple-reaction monitoring were optimized. The
compounds subsequently underwent analysis on an LTQ Orbitrap FT-MS to
conﬁrm the isotopic composition of the product ions chosen. The mass tran-
sitions monitored during tandem mass spectrometry (positive electrospray
mode, spray voltage 3.25 kV; source temperature 400°C; and collision gas
pressure 1.5 mTorr) were 361→163 m/z for cortisone, 363→165 m/z for d2-
cortisone, 363→121 m/z for cortisol and epi-cortisol (internal standard),
365→122 and 365→329 m/z for d2-cortisol, 366→121 m/z for d3-cortisol, and
367→121 m/z for d4-cortisol, with collision energies and tube lens voltages,
respectively, of 22 and 168 (cortisone), 21 and 118 (d2-cortisone), 31 and 142
(cortisol), 23 and 13 with a tube lens 118 (d2-cortisol), 24 and 142 (d3-cortisol),
and 28 and 142 (d4-cortisol). Concentrations of cortisol, cortisone, and
d2-cortisone were determined using calibration curves. The peak areas of
deuterated steroids were corrected for the abundances of naturally occurring
isotopomers at baseline. In addition, the peak area of d4-cortisol was cor-
rected for interference from the m+4 isotopomer of cortisol and the m+1
isotopomer of d3-cortisol. The peak area of d3-cortisol was corrected for in-
terference from the m+3 isotopomer of cortisol and the m+1 isotopomer of d2-
cortisol. Naturally occurring m+2 isotopomers of cortisone were detected at
,1% and did not exceed background, so a correction was not applied.
Plasma d2-cortisol, d3-cortisol, and d4-cortisol concentrations were calcu-
lated by multiplying the concentrations of cortisol by their respective tracer-to-
tracee ratios. Serum ICG was measured using HPLC as previously described (4).
Data analysis, kinetic calculations, and statistics. Volume of distribution
and half-life of d2-cortisone were calculated following bolus injection using
Kinetica software (Thermo Scientiﬁc, Philadelphia, PA). Clearance was cal-
culated at steady state (ss, 60–180 min) using Equation 1.
Clearance ðL=minÞ ¼
rate of infusion ðnmol=minÞ
steady-state concentration ðnmol=LÞ
ð1Þ
Whole-body Ra of cortisol, Ra d3-cortisol, and net Ra cortisone (nanomoles per
minute) in arterial plasma were calculated by dividing the rate of tracer in-
fusion (nanomoles per minute) by the respective tracer-to-tracee ratio:
Ra cortisol5
rate of d4-cortisol infusion
ðd4-cortisol :cortisolÞ
2 rate of cortisol infusion ð2Þ
Ra d3-cortisol ¼
rate of d4-cortisol infusion
ðd4-cortisol :d3-cortisolÞ
ð3Þ
Net Ra cortisone ¼
rate of d2-cortisone infusion
ðd2-cortisone :cortisoneÞ
ð4Þ
Subcutaneous adipose (pmol/100 g tissue/min) andmuscle tissue (pmol/100 mL
tissue/min) production of cortisol, cortisone, and d3-cortisol were calculated
using arterialized and venous samples (superﬁcial epigastric vein for adipose
and deep forearm vein for forearm skeletal muscle) and blood ﬂow (L/min) at
steady state (180–210 min) using the mean of four samples. Splanchnic glu-
cocorticoid production (nanomoles per min) was calculated using the mean of
three samples and correcting for hepatic blood ﬂow, calculated from the
concentrations of ICG in the hepatic vein and femoral artery as previously
described (4). The following equations were used to calculate tissue gluco-
corticoid release:
Cortisol release ¼ ðBF3½cortisolAÞ3

d4-cortisol :cortisolA
d4-cortisol :cortisolV

2 ðBF3½cortisolAÞ ð5Þ
d3-cortisol release ¼ ðBF3½d3-cortisolA Þ3

d4-cortisol :d3-cortisolA
d4-cortisol :d3-cortisolV

2 ðBF3½d3-cortisolAÞ ð6Þ
Net cortisone release ¼ ðBF3½cortisoneAÞ3

d2-cortisone :cortisoneA
d2-cortisone :cortisoneV

 
2 ðBF3½cortisoneAÞ ð7Þ
where A is arterialized, V is venous, and BF is blood ﬂow.
Data are presented as means 6 SEM and were compared using paired
Student t tests. Differences from zero were calculated using a single-sample
t test. Signiﬁcance was accepted at P , 0.05.
RESULTS
Validation of d2-cortisone tracer. d2-Cortisone was
a substrate for human 11bHSD1 in vitro. Incubation of
HEK293/h11bHSD1 cells with d2-cortisone or cortisone
resulted in production of d2-cortisol or cortisol, respectively
(0.176 0.05 vs. 0.416 0.15 pmol/105 cells/min, P = 0.11). d2-
Cortisone and cortisone had comparable effects in compe-
tition with [3H]2-cortisone: for formation of [
3H]2-cortisol in
the presence of d2-cortisone or cortisone, Vmax was 0.83 6
0.34 and 0.73 6 0.26 pmol/105 cells/min (P = 0.75) and ap-
parent Km 1.60 6 0.84 vs. 0.91 6 0.0.39 mmol/L (P = 0.51),
respectively. In human hepatic cytosol, [3H]2-cortisone
was converted also to [3H]2-3a,5b-tetrahydrocortisone; the
rates of this reaction, catalyzed by 5b-reductase/3aHSD,
were similar for d2-cortisone and cortisone (318.8 6 37.1
vs. 347.3 6 37.9 pmol/mg/h, P = 0.68). [3H]2 Products were
not formed in control samples without cells, cytosol, or
cofactor.
Three men aged 35 6 7 years with BMI 22.8 6 2.1 kg/m2
participated in studies of in vivo pharmacokinetics of d2-
cortisone. After bolus administration, elimination of d2-
cortisone from blood could be ﬁtted with ﬁrst-order
kinetics and the tracer could be detected for 1.5 h after in-
jection (Fig. 1A). Mean plasma half-life was 57.5 min, volume
of distribution 47.0 L, and area under the curve 494 nmol/L
per min. Priming dose and steady-state infusion rates were
estimated from these values.
During primed infusion of d2-cortisone for 3 h, cortisone,
cortisol, d2-cortisone, and d2-cortisol were readily mea-
sured in plasma (Fig. 1B and D). Steady-state d2-cortisone
K.A. HUGHES AND ASSOCIATES
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concentrations were achieved after 15 min. The dilution of
d2-cortisone by endogenous cortisone resulted in a calcu-
lated net Ra of cortisone of 35.6 6 8.8 nmol/min (Table 1).
Licorice administration had effects consistent with in-
hibition of renal 11bHSD2 dehydrogenase activity (30),
lowering endogenous cortisone concentrations without af-
fecting tracer d2-cortisone concentrations or clearance, and
thereby increasing d2-cortisone enrichment and decreasing
the calculated Ra of cortisone (Table 1 and Fig. 1B and C).
Given the small number of participants (n = 3), not all of
these effects of licorice were statistically signiﬁcant.
Cortisol and cortisone recycling in key metabolic
tissues in vivo. For the adipose and skeletal muscle ar-
teriovenous sampling, study participants (n = 6 men) were
aged 30–49 years (mean 6 SEM 42 6 4), with BMI 21–28
kg/m2 (24.6 6 0.9) and fat mass of 10.5–30.5 kg (16.5 6
2.9), and took no regular medications. For the hepatic vein
study, participants (n = 4) were aged 43–70 years (60 6 6),
with BMI 24–26 (25.36 0.6), being investigated for ischemic
heart disease and taking statins (n = 4) and b-adrenergic
receptor blockers (n = 3).
Whole body. Plasma d4-cortisol concentrations and en-
richment of plasma with d4-cortisol and d3-cortisol were
in steady state by 3 h, while plasma d2-cortisone con-
centrations and enrichment were in steady state by 1 h
(Fig. 2). From tracer enrichments at steady state (Table 2),
whole-body cortisol, d3-cortisol, and cortisone produc-
tion were calculated (Table 3). Cortisol production was
similar in the two studies and as previously reported (14).
d3-cortisol production was approximately twice as high in
the adipose and muscle study than in the splanchnic study,
consistent with infusion of a higher enrichment of
d4-cortisol tracer (40 vs. 20%) in the former to ensure detec-
tion in small volumes obtained from adipose veins. Cortisone
production was somewhat higher when d4-cortisol was
coinfused with d2-cortisone, consistent with the additional
source of cortisol as substrate for 11b-dehydrogenase ac-
tivity from the cortisol infusion.
Adipose. Across adipose tissue, there were no arteriove-
nous differences in endogenous steroid or tracer concen-
trations (Table 2). Although there were trends for dilution
of d4-cortisol with both cortisol and d3-cortisol, and once
corrected for blood ﬂow (5.7 6 1.3 mL/min/100 g adipose)
the mean cortisol and d3-cortisol release was consistent
with a magnitude of reductase activity similar to that
detected previously (4), these did not achieve statistical
signiﬁcance (Table 3). By multiplication of dual-energy X-ray
absorptiometry–derived fat mass and local adipose tissue
measurements, whole-body adipose tissue glucocorticoid
release was extrapolated to be ;10% of whole-body values.
However, there was a statistically signiﬁcant fall in plasma
d2-cortisone enrichment (Table 2) and detectable production
of cortisone across subcutaneous adipose tissue (Table 3),
consistent with adipose 11b-dehydrogenase activity. The
ratio of 11b-reductase activity, as measured by Ra of
cortisol, to 11b-dehydrogenase activity was ;1:1.3.
Skeletal muscle. Endogenous and tracer steroid con-
centrations did not change across the forearm circulation/
skeletal muscle except for a fall in d2-cortisone concentra-
tion (Table 2). However, there were signiﬁcant differences
in tracer enrichment, indicating dilution of d4-cortisol with
both cortisol and d3-cortisol and dilution of d2-cortisone with
cortisone (Table 2). Once adjustment was made for fore-
arm blood ﬂow (2.8 6 0.2 mL/100 mL/min), there was
signiﬁcant release of cortisol, d3-cortisol, and cortisone,
indicating both reductase and dehydrogenase activities
(Table 3). The ratio of 11b-reductase activity to 11b-
dehydrogenase activity was ;1:1.
Splanchnic tissues. Across the splanchnic circulation,
there was a fall in d4-cortisol, cortisone, d3-cortisone, and
d2-cortisone concentrations. Enrichment of cortisol with
d4-cortisol and of cortisone with d2-cortisone decreased,
indicating endogenous glucocorticoid production. After
adjustment for hepatic blood ﬂow (0.646 0.11 L/min), there
was signiﬁcant splanchnic release of cortisol, d3-cortisol,
and cortisone (Table 3). The ratio of 11b-reductase to 11b-
dehydrogenase activity was ;3:1.
DISCUSSION
We developed a novel tracer, d2-cortisone, to quantify
cortisone generation for the ﬁrst time in vivo in humans.
This can be attributed to 11b-dehydrogenase activities of
11bHSD2 and/or 11bHSD1, since these are the only enzymes
known to catalyze cortisone generation. Substantial 11b-
dehydrogenase activity is present not only in whole body
(presumably reﬂecting kidney 11bHSD2 activity [31]) but
also in the splanchnic circulation (potentially reﬂecting
11bHSD2 activity in the gut) and in sites where 11bHSD2 is
not expressed signiﬁcantly, including subcutaneous adipose
tissue and forearm skeletal muscle. Although cortisol re-
generation by 11b-reductase predominates in the splanchnic
circulation, there is balanced recycling between cortisol and
cortisone in skeletal muscle and predominant inactivation of
cortisol by 11b-dehydrogenase in adipose tissue. These data
challenge the concept that 11bHSD1 is exclusively a physio-
logical ampliﬁer of glucocorticoid action, suggesting instead
that active recycling between cortisol and cortisone provides
the opportunity for an ampliﬁed dynamic response to alter-
ations in 11bHSD1. Moreover, they suggest, as has been
demonstrated empirically in vitro (32), that 11bHSD1 inhib-
itors may be required to inhibit reductase activity selectively
over dehydrogenase activity in order to lower intracellular
cortisol concentrations and be efﬁcacious; failure to achieve
this might explain lack of efﬁcacy in phase 2 clinical trials (10).
Previously available methods for measuring 11b-
dehydrogenase activity and/or cortisone production are
inadequate. Most investigators relied upon measuring uri-
nary free cortisol–to–cortisone ratios as an index of renal
11bHSD2 activity (33,34) or on urinary cortisol–to–cortisone
metabolite ratios, which reﬂect predominantly intrahepatic
steroid levels. However, these ratios only reﬂect net bal-
ance between the activities of multiple enzymes and do
not quantify rates of turnover between cortisol and cor-
tisone. Others have administered labeled substrates for
TABLE 1
Concentrations of cortisone and d2-cortisone tracer and calculated
kinetic parameters before and after licorice administration
Without
licorice
With
licorice P
Css cortisone (nmol/L) 64.9 6 2.6 24.8 6 4.7 0.02
Css d2-cortisone (nmol/L) 9.3 6 2.1 12.6 6 1.7 0.25
Enrichment d2-cortisone (%) 16.9 6 2.9 43.5 6 8.0 0.08
Net Ra of cortisone (nmol/min) 35.6 6 8.8 15.1 6 4.5 0.17
Clearance d2-cortisone (L/min) 1.04 6 0.8 0.9 6 0.2 0.83
Css cortisol (nmol/L) 238.0 6 33.7 177.9 6 40.5 0.18
Css d2-cortisol (nmol/L) 6.2 6 1.7 18.5 6 5.8 0.19
Data are means 6 SEM for n = 3. Css, concentration at steady state.
d, deuterium.
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11b-dehydrogenase, including 11a-[3H]-cortisol (35), d4-
cortisol (2), 11a-[2H]-cortisol (36), and d2-cortisol (37), but
the removal of these compounds is not exclusively de-
pendent on 11b-dehydrogenase and Ra of 11b-dehydrogenase
product (labeled cortisone or liberated [3H]) cannot be
quantiﬁed accurately in steady state in the absence of
simultaneous measurement of clearance of the product.
Here, we used the gold standard approach, in which en-
dogenous cortisone production is inferred from dilution
of a “tracer” labeled cortisone, infused in steady state. We
selected d2-cortisone because it is available, is distin-
guishable in assays from metabolites of d4-cortisol, and
as a stable isotope can be safely administered and mea-
sured with high speciﬁcity. Cell-based assays conﬁrmed
similar metabolism of cortisone and d2-cortisone.
After in vivo administration, d2-cortisone had a longer
half-life than has been reported for cortisone (58 vs. 28
min) (38). However, the earlier report from the 1950s re-
lied on inferior assay technology. Cortisone production
rate was also higher than the rate measured previously
with a d4-cortisol tracer (by extrapolation from generation of
d3-cortisone) under conditions of non–steady-state kinetics
(36 vs. 24 nmol/min, adjusted for substrate concentration and
volume of distribution [2]). This likely reﬂects the advantages
of making steady-state measurements based on dilution of
tracer by tracee when both tracer and tracee are at phys-
iological concentrations. A limitation of the d2-cortisone
tracer is that it only measures net cortisone production and
cannot account for recycling of cortisol-cortisone in-
terconversion. Moreover, there was a hint in our data,
albeit not statistically signiﬁcant, that the addition of
deuterium to cortisone makes it a worse substrate than
cortisone for 11b-reductase activity. For these reasons,
all 11b-dehydrogenase activities reported here may be
somewhat underestimated. However, the cortisone pro-
duction rate was similar in steady state to the cortisol
production rate; approximately halved by licorice ad-
ministration, consistent with the effect of licorice on
11a-[3H]-cortisol half-life (30); and increased by infusion of
additional cortisol when d4-cortisol tracer was administered.
FIG. 2. Unlabeled and tracer glucocorticoids in plasma from arterialized samples and veins draining skeletal muscle and subcutaneous adipose
tissue. Data are means6 SEM for n = 6 volunteers. Statistical comparisons were conducted on average values in each subject (Table 2). A: Cortisol
concentrations. B: d4-Cortisol–to–cortisol ratio. C: d4-Cortisol–to–d3-cortisol ratio. D: Cortisone concentrations. E: d2-Cortisone–to–cortisone
ratios. ◆, arterialized vein;▲, superﬁcial epigastric vein; □, deep forearm vein. d, deuterium.
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Altogether, these data validate the use of d2-cortisone as
a tracer.
The splanchnic circulation produces more cortisol than
cortisone in individuals being investigated for coronary
artery disease. Indeed, splanchnic release accounts for the
great majority of whole-body d3-cortisol generation by 11b-
reductase, as previously described (4,18,39), but accounts
for less than one-half of whole-body cortisone generation.
However, given the importance of 11bHSD2 in the kidney
(35), which was previously thought to be the exclusive
source of cortisone (31), it is notable that splanchnic cor-
tisone production is substantial. Its origin is uncertain.
11bHSD1 is expressed in visceral fat and the liver (40,41)
and may function as a dehydrogenase. However, although
11bHSD2 expression in adipose and liver is low (15,42,43),
it is highly expressed in the epithelia of the gastrointestinal
tract (44), and this is likely to be the principal mechanism
accounting for cortisone release previously reported in the
portal vein (3,4). Given this contribution of visceral 11b-
dehydrogenase activity, it appears that liver 11bHSD1 is
indeed a predominant reductase, as anticipated. Unlike
skeletal muscle and adipose tissue, other enzymes are
expressed in human liver that remove cortisol and corti-
sone, including A-ring reductases. It is possible that dif-
ferential removal of cortisol or cortisone may inﬂuence
the substrate concentrations and, hence, the balance be-
tween 11b-dehydrogenase and 11b-reductase, respectively.
In adipose tissue, results were not as anticipated, with
substantial 11b-dehydrogenase activity. This conﬁrms pre-
vious ex vivo (13) and in vivo ﬁndings with microdialysis
(14) but using a technique that does not risk dissociation of
11bHSD1 from the colocalized H6PDH and, hence, loss of
NADPH cofactor supply. Remarkably, the dehydrogenase
activity exceeded 11b-reductase activity in adipose tissue in
steady state. The magnitude of 11b-reductase activity as
judged by d3-cortisol release might be underestimated
owing to the recently discovered slow turnover of the intra-
adipose glucocorticoid pool in humans (45) so that accu-
mulation of d3-cortisone substrate to steady state in adipose
may take longer than the duration of infusion. However, this
is not a confounder of the measurement of cortisol released
from adipose 11b-reductase, which was also slower than
the release of cortisone. The source of dehydrogenase ac-
tivity in adipose is likely to be 11bHSD1, as adipose
11bHSD2 transcript levels are very much lower than
11bHSD1 and may not be sufﬁcient to produce measur-
able active protein (13,42,43,46). Adipose tissue 11bHSD1
has been a focus of research since the description of its
upregulation in human obesity (7) and the potent effects of
its manipulation in mice (47), but it has been assumed to be
an exclusive 11b-reductase. However, an artiﬁcial increase
in adipose dehydrogenase activity by transgenic over-
expression of 11bHSD2 in adipocytes is protective against
the adverse metabolic effects of high-fat feeding in mice
(16). The current data suggest that there could be
switching between reductase and dehydrogenase activities
of 11bHSD1 in adipose tissue and that it can no longer be
assumed that intra-adipose glucocorticoid concentrations are
linearly related to 11bHSD1 protein levels.
Skeletal muscle has only been recognized relatively re-
cently as a potentially important site for 11bHSD1 activity.
Previous in vivo studies measuring arteriovenous gradients
TABLE 2
Mean steady-state plasma steroid concentrations and ratios during deuterated cortisol and cortisone infusions
Adipose and skeletal muscle study Splanchnic study
Arterialized
vein
Subcutaneous
adipose vein
Skeletal muscle
vein
Femoral
artery
Hepatic
vein
Cortisol (nmol/L) 263.8 6 30.6 254.1 6 30.3 271.9 6 31.2 368.9 6 26.2 336.4 6 49.6
d3-Cortisol (nmol/L) 60.0 6 6.0 59.2 6 5.9 63.0 6 6.4 32.0 6 3.9 37.6 6 7.3
d4-Cortisol (nmol/L) 76.3 6 6.9 73.3 6 8.4 77.3 6 7.9 50.6 6 7.4 36.9 6 9.0††
d4-Cortisol–to–d3-cortisol ratio 1.3 6 0.1 1.2 6 0.0 1.2 6 0.0† 1.47 6 0.1 0.89 6 0.1†
d4-Cortisol enrichment [d4-cortisol/
(cortisol + d4-cortisol) 3 100], % 22.8 6 1.3 22.6 6 1.4 22.4 6 1.2† 11.9 6 0.8 9.6 6 0.7†††
Cortisone (nmol/L) 42.0 6 5.3 42.0 6 7.8 40.6 6 4.6 56.4 6 8.3 9.2 6 0.9††
d2-Cortisone (nmol/L) 4.1 6 0.4 4.0 6 0.7 3.6 6 0.6†† 4.7 6 0.3 0.4 6 0.1†††
d2-Cortisone enrichment [d2-cortisone/
(cortisone + d2-cortisone) 3 100), % 7.2 6 0.6 6.5 6 0.7† 6.6 6 0.6† 8.4 6 1.6 4.0 6 0.7
Data are means 6 SEM for the average from each subject in serial samples obtained over 30 min after at least 3 h of tracer infusion in n = 6
men for adipose and skeletal muscle study and n = 4 men for splanchnic study. †P , 0.05, ††P, 0.01, †††P , 0.001 comparing arterialized vs.
venous measurements using Student paired t test. d, deuterium.
TABLE 3
Calculated steady-state kinetic parameters for cortisol and cortisone generation in adipose tissue, skeletal muscle, and splanchnic
tissues
Adipose and skeletal muscle study Splanchnic study
Whole body
(nmol/min)
Subcutaneous adipose
(pmol/100 g/min)
Skeletal muscle
(pmol/100 mL/min)
Whole body
(nmol/min)
Splanchnic
(nmol/min)
Ra cortisol 62.6 6 8.4† 29.3 6 21.1 19.7 6 4.1† 63.5 6 2.3†† 64.0 6 11.4†
Ra d3-cortisol 24.9 6 1.0†† 11.4 6 7.9 5.9 6 1.8† 11.0 6 0.8†† 12.9 6 2.1†
Net Ra cortisone 65.1 6 6.9†† 38.7 6 13.0† 15.2 6 5.8† 65.2 6 4.6†† 19.5 6 2.8†
Data are means 6 SEM for n = 6 men in the adipose and skeletal muscle study and n = 4 in the splanchnic study. †P , 0.05, ††P , 0.001 vs.
zero using single-sample t tests. d, deuterium.
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in total cortisol and cortisone concentrations failed to dem-
onstrate forearm 11bHSD1-reductase activity (20,48,49), de-
spite skeletal muscle 11bHSD1 expression (17). However,
this may be explained by balanced recycling between
cortisol and cortisone, as revealed here with stable iso-
tope tracers. Using d4-cortisol, 11b-reductase activity
has been detected in the leg of obese subjects (18,21).
We show that there is both 11b-reductase and 11b-
dehydrogenase activity in human forearm, albeit of lower
magnitude than in adipose tissue. Since skeletal muscle
blood ﬂow accounts for most of forearm blood ﬂow when
the hand is excluded from the circulation, the 11b-
reductase activity can most likely be attributed to 11bHSD1
in the rhabdomyocytes (17). The 11b-dehydrogenase activity
may be due to reversibility of 11bHSD1 in rhabdomyocytes,
as in adipose tissue, but might also be due to 11bHSD2
expressed within skeletal muscle. 11bHSD2 has been
reported in skeletal muscle vascular and interstitial cells
and in rhabdomyocytes (22), although other investigators
have not replicated these ﬁndings in needle biopsy muscle
samples (23,50).
In conclusion, these data obtained with novel tools
provide key new insights into the physiology of glucocor-
ticoid metabolism in key metabolic tissues in humans. The
number of participants is relatively small and so, although
sufﬁcient for paired comparisons of reductase and de-
hydrogenase activities within individuals, is insufﬁcient
to estimate biological variability, for example in relation to
obesity or variations in regulators of 11bHSD1 expression.
In addition, the hepatic vein samples were obtained in
different participants from the skeletal muscle and adipose
samples, so comparison between tissues must be cautious.
However, we speculate that since recycling between active
cortisol and inert cortisone is an energy-consuming pro-
cess, it is likely to have a physiological advantage. More
work is required to understand whether glucocorticoid
recycling occurs within each cell by 11bHSD functioning
as both reductase and dehydrogenase (autocrine recycling)
or whether recycling occurs in neighboring cells (paracrine
recycling); this requires in vivo studies beyond the reach of
current methodologies. As in other “futile recycling” in
metabolic pathways, recycling between cortisol and corti-
sone within tissues may confer a more dynamic response
to variation either in 11bHSDs themselves or in substrate
availability. Moreover, in the basal state it appears that liver
metabolism is set in favor of cortisol regeneration, while
adipose metabolism may be set in favor of cortisol in-
activation. This insight calls for a reappraisal of our un-
derstanding of the consequences of tissue-speciﬁc disruption
of 11bHSD1 in obesity and the basis for targeting 11bHSD1
as a treatment for metabolic syndrome.
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